세계의 엑소좀 시장 규모, 점유율, 성장 분석 : 용도별, 제품 유형별, 최종사용자별, 워크플로우별, 생체분자 유형별 - 업계 예측(2022-2028년)
Global Exosomes Market Size, Share, Growth Analysis, By Application, By Product, By End-User, By Workflow, By Biomolecule Type - Industry Forecast 2022-2028
세계의 엑소좀 시장 규모는 2022년 1,122억 5,000만 달러에서 2030년까지 8조 7,939억 5,000만 달러에 달하며, 예측 기간(2023-2030년)에 CAGR로 32.75%의 성장이 예측됩니다. 연구 활동의 활발화, 기술의 진보, 바이오테크놀러지 기업 및 제약기업에 의한 투자의 증가에 의해 시장의 확대가 전망됩니다.
세계의 엑소좀 시장에 대해 조사분석했으며, 시장 역학과 전망, 부문 분석, 기업 개요 등을 제공하고 있습니다.
Exosomes Market size was valued at USD 84.49 billion in 2021 and is poised to grow from USD 112.25 billion in 2022 to USD 8793.95 billion by 2030, growing at a CAGR of 32.75% in the forecast period (2023-2030).
The global exosomes market refers to the commercial activities related to the isolation, purification, and characterization of exosomes, which are extracellular vesicles secreted by most cell types. Exosomes play important roles in intercellular communication, and their diagnostic and therapeutic potential is being explored in various fields, including cancer, regenerative medicine, and drug delivery. The market is expected to grow due to increasing research activities, technological advancements, and rising investments by biotechnology and pharmaceutical companies. However, challenges such as standardization, scalability, and regulatory issues need to be addressed for the successful translation of exosome-based products into clinical practice.
Top-down and bottom-up approaches were used to estimate and validate the size of Exosomes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Segments covered in this report
The Global Exosomes Market is segmented based on the Application, Product, End-User, and region. Based on the Application, the Market is segmented into diagnostic and therapeutic applications. Based on the Product, the Market is segmented into instruments, reagents, and software. Based on the End-User, the Market is segmented as cancer institute, hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations). Based on Region it is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.
The development of novel drugs and medical devices involves substantial investments from pharmaceutical, biopharmaceutical, and medical device companies. These businesses allocate significant resources to research and development (R&D) in order to offer innovative and top-quality products to the market. As per current patterns, major players in the pharmaceutical industry are boosting their R&D efficiency by making substantial and enduring investments in R&D, as well as by collaborating on joint R&D ventures. This strategy helps these companies to remain at the forefront of the industry and continue to bring new and improved products to consumers.
The field of exosome research is still in its early stages, lacking established standards. As a result, professionals readily adopt new techniques and processes available on the market. In addition to the challenges of exosome creation, scientists face obstacles in their research, development, and manufacturing. Recently, exosomes derived from MSCs have garnered attention due to their function as intercellular messengers. These unique properties make them attractive for scientific applications such as cancer diagnostics, vaccine development, gene therapy, cell treatment, and drug administration. Therefore, to successfully harvest exosomes and establish industry-leading standards for their purification and characterization, developers of MSC-exosome treatments must adapt their stem cell-free therapy process to meet the demands of exosome manufacturing.
Exosomes have emerged as a promising treatment approach for various ailments, including COVID-19. These tiny vesicles have been utilized in the medical field to transport therapeutic payloads, circumventing issues like immune rejection and cellular harm. As a cell-free alternative, they offer a potential solution for treating diverse diseases and promoting tissue repair. Specifically, exosomal therapy targeted towards respiratory viral infections, such as SARS-CoV-2, can be developed using stem cell-derived exosomes, which possess favorable anti-inflammatory and regenerative traits inherited from their parent cells.